WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...
(RTTNews) - Viridian Therapeutics (VRDN) Monday has granted 113,200 stock options to nine new employees and 310,700 stock options to newly appointed Chief Medical Officer, Dr. Radhika Tripuraneni.
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Viridian Therapeutics Inc (Symbol: VRDN) entered into oversold territory, hitting an RSI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback